Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Emmaus Life Sciences, Inc. (EMMA) had Revenue of $16.65M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$16.65M
Net Income	$-6.45M
Cost of Goods Sold	$1.20M
Gross Profit	$15.45M
Operating Expenses	$18.55M
Operating Income	$-1.89M
Non-Operating Income/Expense	$-4.53M
Pre-Tax Income	$-6.42M
Normalized Pre-Tax Income	$-5.88M
Income after Taxes	$-6.45M
Income from Continuous Operations	$-6.45M
Consolidated Net Income/Loss	$-6.45M
Normalized Income after Taxes	$-5.91M
EBIT	$-1.89M
EBITDA	$-1.16M
Weighted-Average Shares Outstanding (Basic)	63.23M
Weighted-Average Shares Outstanding (Diluted)	63.23M
Earnings per Share (EPS) (Basic)	$-0.10
Earnings per Share (EPS) (Diluted)	$-0.10
Balance Sheet Financials
Current Assets	$6.77M
Property, Plant, and Equipment	$0.05M
Long-Term Assets	$16.84M
Total Assets	$23.60M
Current Liabilities	$63.55M
Long-Term Debt	$2.25M
Long-Term Liabilities	$16.53M
Total Liabilities	$80.08M
Common Equity	$-56.48M
Tangible Shareholders Equity	$-56.48M
Shareholders Equity	$-56.48M
Common Shares Outstanding	63.87M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-2.29M
Cash Flow from Investing Activities	$2.50M
Cash Flow from Financial Activities	$-1.35M
Beginning Cash	$2.55M
End Cash	$1.39M
Increase/Decrease in Cash	$-1.16M
Stock-Based Compensation	$0.26M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.11
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-0.04
Debt to Equity Ratio	-0.53
Gross Margin	92.79%
Operating Margin	-11.37%
EBIT Margin	-11.37%
EBITDA Margin	-6.99%
Pre-Tax Profit Margin	-38.58%
Profit Margin	-38.75%
Free Cash Flow	$-2.29M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.71
Inventory Turnover	0.73
Receiveable Turnover	6.35
Days Sales in Receivables	57.49
Return on Equity	11.43%
Return on Tangible Equity	11.43%
Return on Assets	-27.34%
Return on Investments	11.90%
Book Value Per Share	$-0.88
Free Cash Flow per Share	$-0.04
Operating Cash Flow per Share	$-0.04

Data from Zacks Investment Research, Inc.